Evofem (EVFM) revises Adjuvant convertible note maturity and prepayment terms
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Evofem Biosciences, Inc. entered into a fourth amendment to its Securities Purchase Agreement with Adjuvant Global Health Technology Fund entities covering previously issued convertible promissory notes. The amendment sets the notes’ maturity as the earlier of six months after April 10, 2026, an Adjuvant‑elected change of control, or any contractual acceleration, and restricts prepayment before six months without Adjuvant’s written consent.
Positive
- None.
Negative
- None.
Insights
Evofem tightens terms on Adjuvant notes, clarifying near-term debt timing.
Evofem Biosciences and Adjuvant amended the existing Securities Purchase Agreement governing convertible promissory notes. The key change defines a new maturity trigger: the earlier of six months after April 10, 2026, an Adjuvant‑elected change of control, or acceleration under Section 8.
The amendment also bars prepayment within six months of the Effective Date without Adjuvant’s consent, limiting Evofem’s flexibility to retire this debt early. This keeps the notes outstanding for at least that period, unless a change of control or default‑style acceleration occurs.
Overall, this is a targeted legal and timing adjustment to existing financing, without disclosed note amounts or pricing in the excerpt. Its practical impact will depend on Evofem’s liquidity position and any future corporate transactions, as described in subsequent company disclosures.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Effective Date: April 10, 2026
Minimum period before prepayment: six months
2 metrics
Effective Date
April 10, 2026
Start date for revised note maturity calculation
Minimum period before prepayment
six months
Notes cannot be prepaid within six months after April 10, 2026 without Adjuvant consent
Key Terms
Material Definitive Agreement, Securities Purchase Agreement, convertible promissory notes, Change of Control, +1 more
5 terms
Material Definitive Agreement regulatory
"Item 1.01 Entry into a Material Definitive Agreement Amendment to Securities Purchase Agreement"
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
Securities Purchase Agreement financial
"entered into a fourth amendment (the “Fourth Amendment”) to the Securities Purchase Agreement dated as of October 14, 2020"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
convertible promissory notes financial
"pursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the “Notes”)."
A convertible promissory note is a loan a company takes that can later be turned into shares instead of being paid back in cash; think of lending money now in exchange for a voucher that can become ownership later. Investors care because it mixes credit risk and potential ownership upside—it can protect lenders if a company struggles while also diluting existing shareholders when converted, affecting future share value and investor returns.
Change of Control financial
"at the election of Adjuvant, the date of a consummation of a Change of Control (as defined in the Securities Purchase Agreement)"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
Maturity Date financial
"Section 8 (the “Maturity Date”, as per the Securities Purchase Agreement)."
The maturity date is the specific day when a loan, bond, or investment reaches its full term and the borrower must repay the borrowed amount in full. It is important for investors because it indicates when they will receive their initial money back and can plan their future financial steps accordingly. Think of it as the due date for a loan or the day a gift card or coupon expires.
FAQ
What agreement did Evofem Biosciences (EVFM) amend with Adjuvant on April 10, 2026?
Evofem Biosciences amended its existing Securities Purchase Agreement with Adjuvant funds that covers certain convertible promissory notes. The fourth amendment updates when those notes become due and payable and clarifies conditions tied to change of control events and potential acceleration under the agreement.
How did the April 2026 amendment change the maturity of Evofem’s Adjuvant notes?
The amendment sets the notes’ maturity as the earlier of six months after April 10, 2026, an Adjuvant‑elected change of control, or any acceleration under Section 8. This defines a clearer timeframe and event-based triggers for when the notes must be paid in full by Evofem.
Can Evofem Biosciences (EVFM) prepay the Adjuvant convertible notes after the amendment?
Under the amendment, Evofem may not prepay the notes before six months after April 10, 2026, without Adjuvant’s prior written consent. This restriction ensures the notes remain outstanding for at least that initial six‑month period unless a qualifying change of control or acceleration event occurs.
Who are the Adjuvant entities involved in Evofem Biosciences’ amended note agreement?
The counterparties are Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P. Together referred to as “Adjuvant,” they previously purchased convertible promissory notes from Evofem and now agreed to the fourth amendment governing those securities’ key terms.
What is the Effective Date of Evofem Biosciences’ fourth amendment with Adjuvant?
The Effective Date of the fourth amendment is April 10, 2026. This date anchors the revised maturity calculation for the convertible notes, which now become due the earlier of six months after that date, an Adjuvant‑elected change of control, or an acceleration event under Section 8.